Fixed dosing of HER antibodies

What is this patent about?

’184 is related to the field of oncology and pharmacology, specifically focusing on the administration of monoclonal antibodies for cancer therapy. The invention addresses the treatment of tumors that express human epidermal growth factor receptor 2 (HER2), a protein often associated with aggressive cell growth in breast, ovarian, and other carcinomas. Traditionally, these biological therapies are administered using weight-based or body-surface-area-based calculations to account for patient variability, a process that introduces complexity and potential for dosing errors in clinical settings.

The underlying idea behind ’184 is that the pharmacokinetic variability of the HER2 antibody pertuzumab is not significantly reduced by individualizing doses based on a patient’s weight or size. Through population modeling, the inventors discovered that while body weight and surface area do influence how the drug moves through the body, they only explain a small fraction of the differences between patients. Consequently, the invention shifts the paradigm from complex calculations to a fixed-dose regimen, providing a standardized amount of the antibody that maintains therapeutic drug levels across a diverse patient population.

The claims of ’184 focus on standardized dosing amounts for treating HER2-expressing cancers in human patients. Specifically, the independent claims protect methods of administration where the antibody—defined by specific variable light and heavy amino acid sequences (SEQ ID Nos. 3 and 4) or identified as pertuzumab—is delivered in fixed quantities of approximately 420 mg, 525 mg, 840 mg, or 1050 mg. This legal focus ensures that the therapeutic effect is achieved through a simplified clinical protocol rather than individualized titration.

In practice, the invention is implemented by delivering a high-concentration loading dose, such as 840 mg, followed by periodic maintenance doses of 420 mg every three weeks. This approach utilizes a two-compartment linear model to ensure that the drug concentration in the patient's serum remains above a target threshold, typically 20 mcg/mL, which is necessary to inhibit the dimerization of HER2 with other receptors like HER3. By preventing these receptors from pairing, the antibody effectively cuts off the signaling pathways that drive tumor proliferation and survival.

This approach differs from prior solutions by eliminating the need for mg/kg or mg/m² calculations, which were previously thought essential for monoclonal IgG1 antibodies. The invention demonstrates that a flat dose is just as effective at managing the trough concentrations of the drug as individualized dosing, even for patients at extreme ends of the weight spectrum. By moving to a single-unit dose, the method improves hospital efficiency, reduces the risk of pharmacy calculation errors, and streamlines the manufacturing and distribution of life-saving cancer treatments.